申请人:SMITH KLINE & FRENCH LABORATORIES
LIMITED
公开号:EP0400799A1
公开(公告)日:1990-12-05
Compounds of the formula (I) :
and pharmaceutically acceptable salts thereof are described wherein R¹ is C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₅cycloalkylC₁₋₆alkyl, phenylC₁₋₆alkyl or C₁₋₆alkyl substituted by 1 to 6 fluoro groups; and R² is hydrogen, amino, -NHCOR³, or -CONR⁴R⁵, wherein R³ is C₁₋₆alkyl, R⁴ is C₁₋₆alkyl and R⁵ is hydrogen or C₁₋₆alkyl. Processes for their preparation, pharmaceutical compositions comprising them and their use as medicaments are also described.
式 (I) :
及其药学上可接受的盐,其中 R¹ 是 C₁₋₆、C₂₋₆烷基、C₃₋₅烷基、苯基 C₁₋₆ 烷基或被 1 至 6 个氟基团取代的 C₁₋₆ 烷基;和 R² 是氢、氨基、-NHCOR³ 或 -CONR⁴R⁵,其中 R³ 是 C₁₋₆烷基,R⁴ 是 C₁₋₆ 烷基,R⁵ 是氢或 C₁₋₆烷基。此外,还介绍了它们的制备工艺、包含它们的药物组合物以及它们作为药物的用途。